Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease? Available to Purchase

https://doi.org/10.1164/rccm.201807-1255st

2.

Raghu

G

,

Remy-Jardin

M

,

Myers

JL

,

Richeldi

L

,

Ryerson

CJ

,

Lederer

DJ

,

Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline

.

Am J Respir Crit Care Med

.

2018

;

198

(

5

):

e44

–

68

.

.

https://doi.org/10.1164/rccm.201308-1483ST

3.

Travis

WD

,

Costabel

U

,

Hansell

DM

,

King

TE

Jr.,

King

DA

,

Nicholson

AG

,

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

.

Am J Respir Crit Care Med

.

2013

;

188

(

6

):

733

–

48

.

.

https://doi.org/10.1056/NEJMra1705751

4.

Lederer

DJ

,

Martinez

FJ

.

Idiopathic pulmonary fibrosis

.

N Engl J Med

.

2018

;

378

(

19

):

1811

–

23

.

.

https://doi.org/10.1016/S2213-2600(17)30433-2

5.

Lynch

DA

,

Sverzellati

N

,

Travis

WD

,

Brown

KK

,

Colby

TV

,

Galvin

JR

,

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

.

Lancet Respir Med

.

2017

;

6

:

138

–

53

.

.

https://doi.org/10.1146/annurev-pathol-012513-104706

6.

Wolters

PJ

,

Collard

HR

,

Jones

KD

.

Pathogenesis of idiopathic pulmonary fibrosis

.

Annu Rev Pathol Mech Dis

.

2014

;

9

(

1

):

157

–

79

.

.

https://doi.org/10.1164/rccm.201506-1063ST

7.

Raghu

G

,

Rochwerg

B

,

Zhang

Y

,

Garcia

CA

,

Azuma

A

,

Behr

J

,

An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline

.

Am J Respir Crit Care Med

.

2015

;

192

(

2

):

e3

–

19

.

.

https://doi.org/10.1186/1755-1536-3-16

8.

Macías-Barragán

J

,

Sandoval-Rodríguez

A

,

Navarro-Partida

J

,

Armendáriz-Borunda

J

.

The multifaceted role of pirfenidone and its novel targets

.

Fibrogenesis Tissue Repair

.

2010

;

3

(

1

):

16

.

.

https://doi.org/10.1016/S0140-6736(11)60405-4

9.

Noble

PW

,

Albera

C

,

Bradford

WZ

,

Costabel

U

,

Glassberg

MK

,

Kardatzke

D

,

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

.

Lancet

.

2011

;

377

(

9779

):

1760

–

9

.

.

https://doi.org/10.1056/NEJMoa1402582

10.

King

TE

Jr,

Bradford

WZ

,

Castro-Bernardini

S

,

Fagan

EA

,

Glaspole

I

,

Glassberg

MK

,

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

.

N Engl J Med

.

2014

;

370

(

22

):

2083

–

92

.

.

https://doi.org/10.1164/rccm.201701-0091OC

11.

Ley

B

,

Swigris

J

,

Day

BM

,

Stauffer

JL

,

Raimundo

K

,

Chou

W

,

Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis

.

Am J Respir Crit Care Med

.

2017

;

196

(

6

):

756

–

61

.

.

https://doi.org/10.1183/09031936.00174914

12.

Wollin

L

,

Wex

E

,

Pautsch

A

,

Schnapp

G

,

Hostettler

KE

,

Stowasser

S

,

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

.

Eur Respir J

.

2015

;

45

(

5

):

1434

–

45

.

.

https://doi.org/10.1056/NEJMoa1103690

13.

Richeldi

L

,

Costabel

U

,

Selman

M

,

Kim

DS

,

Hansell

DM

,

Nicholson

AG

,

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

.

N Engl J Med

.

2011

;

365

(

12

):

1079

–

87

.

.

https://doi.org/10.1056/NEJMoa1402584

14.

Richeldi

L

,

Du Bois

RM

,

Raghu

G

,

Azuma

A

,

Brown

KK

,

Costabel

U

,

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

.

N Engl J Med

.

2014

;

370

(

22

):

2071

–

82

.

.

15.

Richeldi

L

,

Cottin

V

,

Du Bois

RM

,

Selman

M

,

Kimura

T

,

Bailes

Z

,

Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS^® trials

.

Respir Med

.

2016

;

113

:

74

–

9

.

https://doi.org/10.1183/16000617.0100-2018

16.

Cottin

V

,

Wollin

L

,

Fischer

A

,

Quaresma

M

,

Stowasser

S

,

Harari

S

.

Fibrosing interstitial lung diseases: knowns and unknowns

.

Eur Respir Rev

.

2019

;

28

(

151

):

180100

.

.

17.

Wells

AU

,

Brown

KK

,

Flaherty

KR

,

Kolb

M

,

Thannickal

VJ

.

What’s in a name? That which we call IPF, by any other name would act the same

.

Eur Respir J

.

2018

;

51

:

1800692

.

https://doi.org/10.1186/s12931-019-1022-1

18.

Kolb

M

,

Vašáková

M

.

The natural history of progressive fibrosing interstitial lung diseases

.

Respir Res

.

2019

;

20

(

1

):

57

–

8

.

.

https://doi.org/10.1183/13993003.00161-2019

19.

Wollin

L

,

Distler

JHW

,

Redente

EF

,

Riches

DWH

,

Stowasser

S

,

Schlenker-Herceg

R

,

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

.

Eur Respir J

.

2019

;

54

(

3

):

1900161

.

.

https://doi.org/10.1183/16000617.0074-2018

20.

Richeldi

L

,

Varone

F

,

Bergna

M

,

De Andrade

J

,

Falk

J

,

Hallowell

R

,

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence

.

Eur Respir Rev

.

2018

;

27

(

150

):

180074

.

.

https://doi.org/10.1056/NEJMoa1908681

21.

Flaherty

KR

,

Wells

AU

,

Cottin

V

,

Devaraj

A

,

Walsh

SLF

,

Inoue

Y

,

Nintedanib in progressive fibrosing interstitial lung diseases

.

N Engl J Med

.

2019

;

381

(

18

):

1718

–

27

.

.

https://doi.org/10.1016/S2213-2600(19)30341-8

22.

Maher

TM

,

Corte

TJ

,

Fischer

A

,

Kreuter

M

,

Lederer

DJ

,

Molina-Molina

M

,

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

.

Lancet Respir Med

.

2020

;

8

(

2

):

147

–

57

.

.

https://doi.org/10.1007/s10067-019-04720-0

23.

Fischer

A

,

Distler

J

.

Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases

.

Clin Rheumatol

.

2019

;

38

(

10

):

2673

–

81

.

.

https://doi.org/10.1097/MCP.0000000000000508

24.

Kouranos

V

,

Miranda

G

,

Corte

TJ

,

Renzoni

EA

.

New treatment paradigms for connective tissue disease-associated interstitial lung disease

.

Curr Opin Pulm Med

.

2018

;

24

(

5

):

453

–

60

.

.

https://doi.org/10.3390/jcm9020407

25.

Vacchi

C

,

Sebastiani

M

,

Cassone

G

,

Cerri

S

,

Della Casa

G

,

Salvarani

C

,

Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review

.

JCM

.

2020

;

9

(

2

):

407

.

.

26.

Wells

AU

,

Flaherty

KR

,

Brown

KK

,

Inoue

Y

,

Devaraj

A

,

Richeldi

L

,

Nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

.

Lancet Respir Med

.

2020

;

8

:

453

–

60

.

https://doi.org/10.1056/NEJMoa1903076

27.

Distler

O

,

Highland

KB

,

Gahlemann

M

,

Azuma

A

,

Fischer

A

,

Mayes

MD

,

Nintedanib for systemic sclerosis-associated interstitial lung disease

.

N Engl J Med

.

2019

;

380

(

26

):

2518

–

28

.

.

https://doi.org/10.3899/jrheum.151322

28.

Clinicaltrials.gov

.

Scleroderma lung study III: combining pirfenidone with mycophenolate (SLS III)

.

2020

. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03221257#moreinfo Accessed 2021 Jan 4.

29.

Khanna

D

,

Albera

C

,

Fischer

A

,

Khalidi

N

,

Raghu

G

,

Chung

L

,

An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated Interstitial Lung disease: the LOTUSS trial

.

J Rheumatol

.

2016

;

43

(

9

):

1672

–

9

.

.

https://doi.org/10.1056/NEJMoa1801562

30.

Juge

PA

,

Lee

JS

,

Ebstein

E

,

Furukawa

H

,

Dobrinskikh

E

,

Gazal

S

,

MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease

.

N Engl J Med

.

2018

;

379

(

23

):

2209

–

19

.

.

https://doi.org/10.1007/s12325-019-01086-2

31.

Solomon

JJ

,

Danoff

SK

,

Goldberg

HJ

,

Woodhead

F

,

Kolb

M

,

Chambers

DC

,

The design and rationale of the trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease

.

Adv Ther

.

2019

;

36

(

11

):

3279

–

87

.

.

32.

Redente

E

,

Aguilar

M

,

Lalire

L

,

Edelman

B

,

Wollin

L

,

Riches

D

.

Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease

.

Eur Respir J

.

2016

;

48

(

Suppl 60

):

PA3089

.

https://doi.org/10.1007/s10067-009-1110-6

33.

Chen

IJ

,

Jan Wu

YJ

,

Lin

CW

,

Fan

KW

,

Luo

SF

,

Ho

HH

,

Interstitial lung disease in polymyositis and dermatomyositis

.

Clin Rheumatol

.

2009

;

28

(

6

):

639

–

46

.

.

https://doi.org/10.1093/rheumatology/kes167

34.

Chua

F

,

Higton

AM

,

Colebatch

AN

,

O’Reilly

K

,

Grubnic

S

,

Vlahos

I

,

Idiopathic inflammatory myositis-associated interstitial lung disease: Ethnicity differences and lung function trends in a British cohort

.

Rheumatology

.

2012

;

51

(

10

):

1870

–

6

.

.

35.

Ji

SY

,

Zeng

FQ

,

Guo

Q

,

Tan

GZ

,

Tang

HF

,

Luo

YJ

,

Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study

.

Chin Med J

.

2010

;

123

(

5

):

517

–

22

.

https://doi.org/10.1002/art.30513

36.

Marie

I

,

Hatron

PY

,

Dominique

S

,

Cherin

P

,

Mouthon

L

,

Menard

JF

.

Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients

.

Arthritis Rheum

.

2011

;

63

(

11

):

3439

–

47

.

.

37.

Huh

JW

,

Kim

DS

,

Lee

C-K

,

Yoo

B

,

Seo

JB

,

Kitaichi

M

,

Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis

.

Respir Med

.

2007

;

101

:

1761

–

9

.

https://doi.org/10.1007/s10067-007-0562-9

38.

Ye

S

,

Chen

XX

,

Lu

XY

,

Wu

MF

,

Deng

Y

,

Huang

WQ

,

Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study

.

Clin Rheumatol

.

2007

;

26

(

10

):

1647

–

54

.

.

https://doi.org/10.1371/journal.pone.0098824

39.

Fujisawa

T

,

Hozumi

H

,

Kono

M

,

Enomoto

N

,

Hashimoto

D

,

Nakamura

Y

,

Prognostic factors for myositis-associated interstitial lung disease

.

PLoS One

.

2014

;

9

(

6

):

e98824

.

.

https://doi.org/10.2169/internalmedicine.49.2889

40.

Koreeda

Y

,

Higashimoto

I

,

Yamamoto

M

,

Takahashi

M

,

Kaji

K

,

Fujimoto

M

,

Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies

.

Intern Med

.

2010

;

49

(

5

):

361

–

9

.

.

https://doi.org/10.1002/acr.21895

41.

Marie

I

,

Josse

S

,

Hatron

PY

,

Dominique

S

,

Hachulla

E

,

Janvresse

A

,

Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome

.

Arthritis Care Res

.

2013

;

65

(

5

):

800

–

8

.

.

https://doi.org/10.1016/j.semarthrit.2016.03.011

42.

Trallero-Araguás

E

,

Grau-Junyent

JM

,

Labirua-Iturburu

A

,

García-Hernández

FJ

,

Monteagudo-Jiménez

M

,

Fraile-Rodriguez

G

,

Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group

.

Semin Arthritis Rheum

.

2016

;

46

(

2

):

225

–

31

.

.

https://doi.org/10.1159/000488358

43.

Yamakawa

H

,

Hagiwara

E

,

Kitamura

H

,

Iwasawa

T

,

Otoshi

R

,

Aiko

N

,

Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies

.

Respiration

.

2018

;

96

(

3

):

210

–

21

.

.

https://doi.org/10.1164/ajrccm.164.7.2103110

44.

Douglas

WW

,

Tazelaar

HD

,

Hartman

TE

,

Hartman

RP

,

Decker

PA

,

Schroeder

DR

,

Polymyositis-dermatomyositis-associated interstitial lung disease

.

Am J Respir Crit Care Med

.

2001

;

164

(

7

):

1182

–

5

.

.

https://doi.org/10.1002/art.24631

45.

Richards

TJ

,

Eggebeen

A

,

Gibson

K

,

Yousem

S

,

Fuhrman

C

,

Gochuico

BR

,

Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease

.

Arthritis Rheum

.

2009

;

60

(

7

):

2183

–

92

.

.

https://doi.org/10.1016/j.humpath.2014.01.018

46.

Yousem

SA

,

Schneider

F

,

Bi

D

,

Oddis

CV

,

Gibson

K

,

Aggarwal

R

.

The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome

.

Hum Pathol

.

2014

;

45

(

6

):

1199

–

204

.

.

https://doi.org/10.5858/arpa.2017-0010-OA

47.

Schneider

F

,

Yousem

SA

,

Oddis

CV

,

Aggarwal

R

.

Pulmonary pathologic manifestations of anti-alanyl-tRNA synthetase (Anti-PL-12)-related inflammatory myopathy

.

Arch Pathol Lab Med

.

2018

;

142

(

2

):

191

–

7

.

.

https://doi.org/10.1016/j.pupt.2015.12.004

48.

Witt

LJ

,

Demchuk

C

,

Curran

JJ

,

Strek

ME

.

Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease

.

Pulm Pharmacol Ther

.

2016

;

36

:

46

–

52

.

.

https://doi.org/10.1016/j.autrev.2014.03.004

49.

Lega

JC

,

Fabien

N

,

Reynaud

Q

,

Durieu

I

,

Durupt

S

,

Dutertre

M

,

The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome

.

Autoimmun Rev

.

2014

;

13

(

9

):

883

–

91

.

.

https://doi.org/10.1093/qjmed/77.1.1019

50.

Marguerie

C

,

Bunn

CC

,

Beynon

HL

,

Bernstein

RM

,

Hughes

JM

,

So

AK

,

Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes

.

Q J Med

.

1990

;

77

(

282

):

1019

–

38

.

.

https://doi.org/10.1097/00005792-199111000-00002

51.

Love

LA

,

Leff

RL

,

Fraser

DD

,

Targoff

IN

,

Dalakas

M

,

Plotz

PH

,

A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups

.

Medicine

.

1991

;

70

(

6

):

360

–

74

.

.

https://doi.org/10.1371/journal.pone.0060442

52.

Hamaguchi

Y

,

Fujimoto

M

,

Matsushita

T

,

Kaji

K

,

Komura

K

,

Hasegawa

M

,

Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: Heterogeneity within the syndrome

.

PLoS One

.

2013

;

8

(

4

):

e60442

.

.

https://doi.org/10.1097/MD.0b013e318260977c

53.

Labirua-Iturburu

A

,

Selva-O'Callaghan

A

,

Vincze

M

,

Dankó

K

,

Vencovsky

J

,

Fisher

B

,

Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: Clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature

.

Medicine

.

2012

;

91

(

4

):

206

–

11

.

.

https://doi.org/10.1007/s100670070030

54.

Schmidt

WA

,

Wetzel

W

,

Friedländer

R

,

Lange

R

,

Sörensen

HF

,

Lichey

HJ

,

Clinical and serological aspects of patients with anti-Jo-1 antibodies--an evolving spectrum of disease manifestations

.

Clin Rheumatol

.

2000

;

19

(

5

):

371

–

7

.

.

https://doi.org/10.1093/rheumatology/kex021

55.

Pinal-Fernandez

I

,

Casal-Dominguez

M

,

Huapaya

JA

,

Albayda

J

,

Paik

JJ

,

Johnson

C

,

A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies

.

Rheumatology

.

2017

;

56

(

6

):

999

–

1007

.

.

https://doi.org/10.1136/annrheumdis-2012-201800

56.

Aggarwal

R

,

Cassidy

E

,

Fertig

N

,

Koontz

DC

,

Lucas

M

,

Ascherman

DP

,

Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients

.

Ann Rheum Dis

.

2014

;

73

(

1

):

227

–

32

.

.

57.

Hirakata

M

,

Suwa

A

,

Nagai

S

,

Kron

MA

,

Trieu

EP

,

Mimori

T

,

Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease

.

J Immunol

.

1999

;

162

(

4

):

2315

–

20

.

https://doi.org/10.1016/j.ejim.2013.01.002

58.

Marie

I

,

Josse

S

,

Decaux

O

,

Diot

E

,

Landron

C

,

Roblot

P

,

Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome

.

Eur J Intern Med

.

2013

;

24

(

5

):

474

–

9

.

.

59.

Kalluri

M

,

Sahn

SA

,

Oddis

CV

,

Gharib

SL

,

Christopher-Stine

L

,

Danoff

SK

,

Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature

.

Chest

.

2009

;

135

:

1550

–

6

.

https://doi.org/10.1016/j.autrev.2012.01.006

60.

Marie

I

,

Josse

S

,

Decaux

O

,

Dominique

S

,

Diot

E

,

Landron

C

,

Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome

.

Autoimmun Rev

.

2012

;

11

(

10

):

739

–

45

.

.

https://doi.org/10.1001/jamaneurol.2017.0934

61.

Noguchi

E

,

Uruha

A

,

Suzuki

S

,

Hamanaka

K

,

Ohnuki

Y

,

Tsugawa

J

,

Skeletal muscle involvement in antisynthetase syndrome

.

JAMA Neurol

.

2017

;

74

(

8

):

992

–

9

.

.

https://doi.org/10.1016/j.autrev.2019.05.002

62.

Vulsteke

JB

,

Satoh

M

,

Malyavantham

K

,

Bossuyt

X

,

De Langhe

E

,

Mahler

M

.

Anti-OJ autoantibodies: rare or underdetected?

Autoimmun Rev

.

2019

;

18

(

7

):

658

–

64

.

.

https://doi.org/10.1007/s00296-011-2323-y

63.

Chen

F

,

Wang

D

,

Shu

X

,

Nakashima

R

,

Wang

G

.

Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis

.

Rheumatol Int

.

2011

;

32

(

12

):

3909

–

15

.

.

https://doi.org/10.1002/acr.21728

64.

Cao

H

,

Pan

M

,

Kang

Y

,

Xia

Q

,

Li

X

,

Zhao

X

,

Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody

.

Arthritis Care Res

.

2012

;

64

(

10

):

1602

–

10

.

.

https://doi.org/10.1002/acr.21985

65.

Chen

Z

,

Cao

M

,

Plana

MN

,

Liang

J

,

Cai

H

,

Kuwana

M

,

Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis

.

Arthritis Care Res

.

2013

;

65

(

8

):

1316

–

24

.

.

https://doi.org/10.1093/rheumatology/ker518

66.

Koga

T

,

Fujikawa

K

,

Horai

Y

,

Okada

A

,

Kawashiri

SY

,

Iwamoto

N

,

The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM

.

Rheumatology

.

2012

;

51

(

7

):

1278

–

84

.

.

https://doi.org/10.3899/jrheum.160682

67.

Moghadam-Kia

S

,

Oddis

CV

,

Sato

S

,

Kuwana

M

,

Aggarwal

R

.

Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north american patients with dermatomyositis

.

J Rheumatol

.

2017

;

44

(

3

):

319

–

25

.

.

https://doi.org/10.1080/03009740802687455

68.

Fujikawa

K

,

Kawakami

A

,

Kaji

K

,

Fujimoto

M

,

Kawashiri

S

,

Iwamoto

N

,

Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study

.

Scand J Rheumatol

.

2009

;

38

(

4

):

263

–

7

.

.

https://doi.org/10.1093/rheumatology/keq153

69.

Hoshino

K

,

Muro

Y

,

Sugiura

K

,

Tomita

Y

,

Nakashima

R

,

Mimori

T

.

Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis

.

Rheumatology

.

2010

;

49

(

9

):

1726

–

33

.

.

https://doi.org/10.1016/j.rmed.2015.07.004

70.

Takada

T

,

Aoki

A

,

Asakawa

K

,

Sakagami

T

,

Moriyama

H

,

Narita

I

,

Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis

.

Respir Med

.

2015

;

109

(

9

):

1174

–

80

.

.

https://doi.org/10.1093/rheumatology/kes102

71.

Gono

T

,

Sato

S

,

Kawaguchi

Y

,

Kuwana

M

,

Hanaoka

M

,

Katsumata

Y

,

Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

.

Rheumatology

.

2012

;

51

(

9

):

1563

–

70

.

.

https://doi.org/10.1093/rheumatology/ker408

72.

Muro

Y

,

Sugiura

K

,

Hoshino

K

,

Akiyama

M

.

Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission

.

Rheumatology

.

2012

;

51

(

5

):

800

–

4

.

.

73.

Hall

JC

,

Casciola-Rosen

L

,

Samedy

L

,

Werner

J

,

Owoyemi

K

,

Danoff

SK

,

Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum

.

Arthritis Care Res

.

2013

;

65

:

1307

–

15

.

https://doi.org/10.1016/j.jaad.2010.09.016

74.

Fiorentino

D

,

Chung

L

,

Zwerner

J

,

Rosen

A

,

Casciola-Rosen

L

.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

.

J Am Acad Dermatol

.

2011

;

65

(

1

):

25

–

34

.

.

75.

Selva-O’Callaghan

A

,

Labrador-Horrillo

M

,

Solans-Laqué

R

,

Simeón-Aznar

CP

,

Martínez-Gómez

X

,

Vilardell-Tarrés

M

.

Myositis-specific and myositis-associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflammatory myopathy

.

Arthritis Rheum

.

2006

;

55

:

791

–

8

.

https://doi.org/10.1093/rheumatology/35.4.305

76.

Venables

PJ

.

Polymyositis-associated overlap syndromes

.

Br J Rheumatol

.

1996

;

35

(

4

):

305

–

6

.

.

https://doi.org/10.3899/jrheum.090652

77.

Lega

JC

,

Cottin

V

,

Fabien

N

,

Thivolet-Béjui

F

,

Cordier

JF

.

Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?

J Rheumatol

.

2010

;

37

(

5

):

1000

–

9

.

.

78.

Fujisawa

T

,

Suda

T

,

Nakamura

Y

,

Enomoto

N

,

Ide

K

,

Toyoshima

M

,

Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis

.

J Rheumatol

.

2005

;

32

(

1

):

58

–

64

.

https://doi.org/10.2169/internalmedicine.37.669

79.

Takada

T

,

Suzuki

E

,

Nakano

M

,

Kagamu

H

,

Tsukada

H

,

Hasegawa

T

,

Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease

.

Intern Med

.

1998

;

37

(

8

):

669

–

73

.

.

https://doi.org/10.3899/jrheum.161217

80.

Sharma

N

,

Putman

MS

,

Vij

R

,

Strek

ME

,

Dua

A

.

Myositis-associated Interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort

.

J Rheumatol

.

2017

;

44

(

11

):

1612

–

8

.

.

https://doi.org/10.3899/jrheum.121043

81.

Fischer

A

,

Brown

KK

,

Du Bois

RM

,

Frankel

SK

,

Cosgrove

GP

,

Fernandez-Perez

ER

,

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease

.

J Rheumatol

.

2013

;

40

(

5

):

640

–

6

.

.

https://doi.org/10.1093/rheumatology/kev004

82.

Andersson

H

,

Sem

M

,

Lund

MB

,

Aaløkken

TM

,

Günther

A

,

Walle-Hansen

R

,

Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease

.

Rheumatology

.

2015

;

54

(

8

):

1420

–

8

.

.

https://doi.org/10.1371/journal.pone.0133702

83.

Allenbach

Y

,

Guiguet

M

,

Rigolet

A

,

Marie

I

,

Hachulla

E

,

Drouot

L

,

Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial

.

PLoS One

.

2015

;

10

(

11

):

e0133702

.

.

https://doi.org/10.1183/09031936.00210414

84.

Saini

G

,

Porte

J

,

Weinreb

PH

,

Violette

SM

,

Wallace

WA

,

McKeever

TM

,

αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease

.

Eur Respir J

.

2015

;

46

(

2

):

486

–

94

.

.

https://doi.org/10.1164/rccm.200706-805OC

85.

Horan

GS

,

Wood

S

,

Ona

V

,

Li

DJ

,

Lukashev

ME

,

Weinreb

PH

,

Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation

.

Am J Respir Crit Care Med

.

2008

;

177

(

1

):

56

–

65

.

.

https://doi.org/10.1165/rcmb.2012-0004OC

86.

Oikonomou

N

,

Mouratis

MA

,

Tzouvelekis

A

,

Kaffe

E

,

Valavanis

C

,

Vilaras

G

,

Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis

.

Am J Respir Cell Mol Biol

.

2012

;

47

(

5

):

566

–

74

.

.

https://doi.org/10.1016/S2213-2600(18)30181-4

87.

Maher

TM

,

Van Der Aar

EM

,

Van De Steen

O

,

Allamassey

L

,

Desrivot

J

,

Dupont

S

,

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): A phase 2a randomised placebo-controlled trial

.

Lancet Respir Med

.

2018

;

6

(

8

):

627

–

35

.

.

https://doi.org/10.2332/allergolint.O-06-449

88.

Nishi

Y

,

Sano

H

,

Kawashima

T

,

Okada

T

,

Kuroda

T

,

Kikkawa

K

,

Role of galectin-3 in human pulmonary fibrosis

.

Allergol Int

.

2007

;

56

(

1

):

57

–

65

.

.

https://doi.org/10.1164/rccm.201509-1753OC

89.

Ho

JE

,

Gao

W

,

Levy

D

,

Santhanakrishnan

R

,

Araki

T

,

Rosas

IO

,

Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities

.

Am J Respir Crit Care Med

.

2016

;

194

(

1

):

77

–

83

.

.

https://doi.org/10.1378/chest.12-0741

90.

Vij

R

,

Strek

ME

.

Diagnosis and treatment of connective tissue disease-associated interstitial lung disease

.

Chest

.

2013

;

143

(

3

):

814

–

24

.

.

https://doi.org/10.1136/bmj.h6819

91.

Mathai

SC

,

Danoff

SK

.

Management of interstitial lung disease associated with connective tissue disease

.

BMJ

.

2016

;

352

:

h6819

.

.

https://doi.org/10.1378/chest.14-3078

92.

Snetselaar

R

,

Van Moorsel

CHM

,

Kazemier

KM

,

Van Der Vis

JJ

,

Zanen

P

,

Van Oosterhout

MFM

,

Telomere length in interstitial lung diseases

.

Chest

.

2015

;

148

(

4

):

1011

–

8

.

.

https://doi.org/10.1183/13993003.01641-2018

93.

Newton

CA

,

Oldham

JM

,

Ley

B

,

Anand

V

,

Adegunsoye

A

,

Liu

G

,

Telomere length and genetic variant associations with interstitial lung disease progression and survival

.

Eur Respir J

.

2019

;

53

(

4

):

1801641

.

.